Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

24

Revenue 2017

Daiichi Sankyo

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Daiichi Sankyo's 2012 sales performance.

Daiichi Sankyo

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Daiichi said today that Seattle Genetics is “claiming certain intellectual property rights related to Daiichi Sankyo’s ADC products”, a stance which it insists is “without merit”. ... The original agreement between the companies cover ADCs

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata

Astellas stays ahead of its FLT3 rivals with EU nod for Xospata Meanwhile, Daiichi Sankyo has said it will concentrate on first-line use of quizartinib after being turned down by regulators in Europe and the US, and says it recently completed enrolment ... There are differences between the two drugs, as quizartinib

Seattle Genetics preps filing next year for oral HER2 drug

Seattle Genetics preps filing next year for oral HER2 drug Competition in the HER2 category is heating up though, with a new antibody-drug conjugate from Daiichi Sankyo and AstraZeneca –  trastuzumab deruxtecan – angling for approval in the US in the second

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs Could add to AZ's portfolio of emerging cancer drugs. AstraZeneca and Daiichi have picked up a priority review from the FDA for their breast cancer therapy trastuzumab deruxtecan, setting up ... Analysts’ expectations for sales potential vary,

Leading AstraZeneca’s return to growth in Europe

Leading AstraZeneca’s return to growth in Europe Looking to build its momentum in oncology even further, AstraZeneca recently signed a huge $6.9bn deal with Daiichi-Sankyo to develop and co-market its next-generation challenger to

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

R&D protocol amendments
Rethinking trials: the pros and cons of protocol amendments
Protocol amendments occur often and can be beneficial, but the steps involved can be complex...
Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...

Infographics